Please ensure Javascript is enabled for purposes of website accessibility

Moderna's Market Value Set to Rise by at Least 75%, Says Noted Analyst

By Eric Volkman - Updated Feb 25, 2021 at 5:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Oppenheimer's Hartaj Singh believes the stock's market capitalization is headed to at least $100 billion.

A long, sustained bull run is in front of Moderna (MRNA 0.03%) stock, if a top analyst's predictions come true. On Thursday, Hartaj Singh, Oppenheimer & Co.'s managing director and senior analyst of biotechnology, said in an interview that the coronavirus vaccine developer could see its market capitalization rise to -- and even surpass -- $100 billion before long.

At the moment, the company is worth over $58 billion.

"I think with Moderna's coronavirus vaccine franchise, and they're also starting to develop flu vaccines which should hit the market in the next couple of years ... you know, we could see a $10 billion franchise five to seven years from now," Singh said in an interview on CNBC's Street Signs Europe program.

"If you put a 10-times-sales multiple on that then, you can do the math, then it's a $100-billion-plus market cap company," he added.

Stethoscope atop $100 bills and pennies.

Image source: Getty Images.

Moderna rose to fame on mRNA-1273, its highly effective coronavirus vaccine. So far, it is one of only two such vaccines to receive Emergency Use Authorization (EUA) from the Food and Drug Administration.

The vaccine is already quite the engine of growth for the company. Also on Thursday, Moderna released its fourth-quarter 2020 results, which showed that it earned revenue of $571 million. Not only was that far above analyst estimates, it was also 40-plus times higher than the year-ago tally. This was due, it nearly goes without saying, to the coronavirus vaccine.

While the company posted a deeper-than-expected net loss, that torrid growth rate (and perhaps Singh's extremely bullish outlook) drove its stock higher on an awful Thursday for the broader market. Moderna closed 2.5% higher, which nearly matched the percentage by which the S&P 500 declined on the day.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$142.85 (0.03%) $0.04
Oppenheimer Holdings Inc. Stock Quote
Oppenheimer Holdings Inc.
$33.04 (-3.70%) $-1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.